Clinical trial
European Trial of Immunosuppression in SPK Tx
NCT00140543 · EUROSPK Study Group, Other · Completed
Key facts
| NCT number | NCT00140543 |
|---|---|
| Title | European Trial of Immunosuppression in SPK Tx |
| Official title | A European Multicenter Open-Label Randomised Trial to Evaluate the Efficacy and Safety of Sirolimus and Tacrolimus Compared to MMF and Tacrolimus With Short-Course Induction Therapy, Short-Term Steroids Application in de Novo SPK Transplanted Diabetic Patients |
| Lead sponsor | EUROSPK Study Group, Other |
| Collaborators | Fujisawa GmbH Industry Hoffmann-La Roche Wyeth is now a wholly owned subsidiary of Pfizer Neovii Biotech Genzyme, a Sanofi Company |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1, Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | sirolimus versus mycophenolate mofetil |
| Enrollment | 228 |
| Start date | Feb 1, 2002 |
| Completion | Sep 30, 2005 |
| First posted | Sep 1, 2005 |
| Last update posted | Aug 23, 2021 |
| Countries | Austria, Belgium, Czechia, Germany, Israel, Spain, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: